Proposed changes in labels for testosterone replacement therapy (TRT) products sent ripples across the space, after the first of a two-day meeting of FDA advisors concluded with a 20-1 vote that the drugs ought only to be used in classic hypogonadism – low testosterone due to testicular or disease of the hypothalamic/pituitary glands.